We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

AstraZeneca plc (AZN) Ordinary US$0.25

Sell:10,504.00p Buy:10,508.00p 0 Change: 244.00p (2.38%)
FTSE 100:1.19%
Market closed Prices as at close on 20 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 244.00p (2.38%)
Market closed Prices as at close on 20 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 244.00p (2.38%)
Market closed Prices as at close on 20 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Contact details

1 Francis Crick Avenue
United Kingdom
+44 (020) 73045000

Important dates

Future events
There are no future events available.
Past events
Quarterly results 29 April 2022 29/04/22
AGM 29 April 2022 29/04/22
Interim dividend payment date 28 March 2022 28/03/22
Interim ex-dividend date 24 February 2022 24/02/22
Annual report 22 February 2022 22/02/22
Final results 10 February 2022 10/02/22
Quarter 4 results 10 February 2022 10/02/22
Quarter 3 results 12 November 2021 12/11/21
Interim dividend payment date 13 September 2021 13/09/21
Interim ex-dividend date 12 August 2021 12/08/21
Quarter 2 results 29 July 2021 29/07/21
Interim results 29 July 2021 29/07/21

General stock information

Market cap:
£162.60 billion
Shares in issue:
1.55 billion
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence
FTSE 100,FTSE 350,FTSE All Share,FTSE techMARK All Share,FTSE 350 Higher Yield

Key personnel

  • Pascal Soriot
    Chief Executive Officer, Executive Director
  • Aradhana Sarin
    Chief Financial Officer, Executive Director
  • Marc Dunoyer
    Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
  • Jeffrey Pott
    Chief Human Resource Officer, General Counsel
  • Katarina Ageborg
    Executive Vice President - Sustainability, Chief Compliance Officer
  • Pam Cheng
    Executive Vice President - Operations and Information Technology
  • Ruud Dobber
    Executive Vice President - BioPharmaceuticals Business Unit
  • David Fredrickson
    Executive Vice President - Oncology Business Unit
  • Menelas Pangalos
    Executive Vice President - Research and Development BioPharmaceuticals
  • Iskra Reic
    Executive Vice President - Vaccines and Immune Therapies

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.